These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18048811)

  • 21. Search for biomarkers of aggressiveness in bladder cancer.
    Egawa S; Kuruma H
    Eur Urol; 2006 Jul; 50(1):20-2. PubMed ID: 16530926
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular markers in bladder cancer.
    Shariat SF; Karam JA; Lerner SP
    Curr Opin Urol; 2008 Jan; 18(1):1-8. PubMed ID: 18090481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.
    Liu HB; Kong CZ; Zeng Y; Liu XK; Bi JB; Jiang YJ; Han S
    Urol Oncol; 2009; 27(3):277-83. PubMed ID: 18555709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
    Kalantari MR; Ahmadnia H
    Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular markers for detection, surveillance and prognostication of bladder cancer.
    Vrooman OP; Witjes JA
    Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of apoptosis and proliferation markers in progression of ovarian cancer].
    Antoneeva II; Petrov SB
    Patol Fiziol Eksp Ter; 2008; (4):6-7. PubMed ID: 19198263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.
    Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
    Anticancer Res; 2008; 28(4C):2279-87. PubMed ID: 18751407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
    Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
    J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive biomarkers and signatures in urinary bladder cancer.
    Roos PH; Golka K; Hengstler JG
    Curr Opin Mol Ther; 2008 Jun; 10(3):243-50. PubMed ID: 18535931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pitfalls in immunohistochemical validation of tumor marker expression--exemplified in invasive cancer of the uterine cervix.
    Hellberg D; Tot T; Stendahl U
    Gynecol Oncol; 2009 Jan; 112(1):235-40. PubMed ID: 18976801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
    Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
    Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of myopodin methylation in bladder cancer.
    Cebrian V; Alvarez M; Aleman A; Palou J; Bellmunt J; Gonzalez-Peramato P; Cordón-Cardo C; García J; Piulats JM; Sánchez-Carbayo M
    J Pathol; 2008 Sep; 216(1):111-9. PubMed ID: 18636402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of NFAT signal by p53-K120R mutant.
    Shinmen N; Koshida T; Kumazawa T; Sato K; Shimada H; Matsutani T; Iwadate Y; Takiguchi M; Hiwasa T
    FEBS Lett; 2009 Jun; 583(12):1916-22. PubMed ID: 19416725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.
    Chen W; Luo JH; Hua WF; Zhou FJ; Lin MC; Kung HF; Zeng YX; Guan XY; Xie D
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):400-8. PubMed ID: 19155439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction.
    Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F
    J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer.
    Ahirwar D; Mandhani A; Mittal RD
    Arch Med Res; 2009 Feb; 40(2):97-102. PubMed ID: 19237018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.